UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 648

Sortiert nach

Biomarkers and surrogate endpoints in clinical trials

Statistics in medicine, 2012-11, Vol.31 (25), p.2973-2984

2012

Link zum Volltext

Verfügbarkeit prüfen

Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022

Scientific reports, 2024-02, Vol.14 (1), p.3325-3325

2024

Link zum Volltext

Verfügbarkeit prüfen

Improving the Evidence for New Interventions in Infectious Diseases: Refocusing on Patients Instead of Pathogens and Direct Evidence for Added Patient Benefits

Clinical infectious diseases, 2021-06, Vol.72 (11), p.1975-1978

Powers, John H

2021

Link zum Volltext

Verfügbarkeit prüfen

Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents

Clinical infectious diseases, 2018-11, Vol.67 (12), p.1803-1814

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force

Value in health, 2015-09, Vol.18 (6), p.741-752

2015

Link zum Volltext

Verfügbarkeit prüfen

Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals

The Lancet infectious diseases, 2021-02, Vol.21 (2), p.241-251

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

mBio, 2016-04, Vol.7 (2), p.e00417-e00416

2016

Link zum Volltext

Verfügbarkeit prüfen

Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis

Chest, 2019-06, Vol.155 (6), p.1109-1118

2019

Link zum Volltext

Verfügbarkeit prüfen

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)

Clinical infectious diseases, 2015-09, Vol.61 (5), p.800-806

2015

Link zum Volltext

Verfügbarkeit prüfen

Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients

Antimicrobial agents and chemotherapy, 2022-08, Vol.66 (8), p.e0076622-e0076622

2022

Link zum Volltext

Verfügbarkeit prüfen

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

The Journal of infectious diseases, 2019-05, Vol.219 (10), p.1536-1544

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of 7 vs 14 Days of Antibiotics Among Afebrile Men With Urinary Tract Infection

JAMA : the journal of the American Medical Association, 2021-11, Vol.326 (20), p.2079

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

Value in health, 2017, Vol.20 (1), p.2-14

2017

Link zum Volltext

Verfügbarkeit prüfen

World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine: A Critical Step for Developing Risk Management Strategies for the Use of Antimicrobials in Food Production Animals

Clinical infectious diseases, 2009-07, Vol.49 (1), p.132-141

2009

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation

Value in health, 2020-02, Vol.23 (2), p.227-235

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross‐sectional study

Influenza and other respiratory viruses, 2022-05, Vol.16 (3), p.462-473

2022

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective

Value in health, 2007-11, Vol.10, p.S125-S137

2007

Link zum Volltext

Verfügbarkeit prüfen

Trends in Antimicrobial Drug Development: Implications for the Future

Clinical infectious diseases, 2004-05, Vol.38 (9), p.1279-1286

2004

Link zum Volltext

Verfügbarkeit prüfen

Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study

The Lancet infectious diseases, 2020-10, Vol.20 (10), p.1172-1181

2020

Link zum Volltext

Verfügbarkeit prüfen

Factor Analysis in Distinguishing Coronavirus Disease 2019 From Other Influenza-like Illness Using a Validated Patient-Reported Outcome Instrument FLU-PRO Plus: A Prospective Real-world Cohort Study

Medical care, 2023-05, Vol.61 (5), p.288

2023

Link zum Volltext

Verfügbarkeit prüfen

Fluoroquinolone-Resistant Campylobacter Species and the Withdrawal of Fluoroquinolones from Use in Poultry: A Public Health Success Story

Clinical infectious diseases, 2007-04, Vol.44 (7), p.977-980

2007

Link zum Volltext

Verfügbarkeit prüfen

A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas

Healthcare (Basel), 2023-06, Vol.11 (12), p.1759

2023

Link zum Volltext

Verfügbarkeit prüfen

Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model

BMC infectious diseases, 2018-07, Vol.18 (1), p.353-353, Article 353

2018

Link zum Volltext

Verfügbarkeit prüfen

Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence

PloS one, 2016-08, Vol.11 (8), p.e0159727-e0159727

2016

Link zum Volltext

Verfügbarkeit prüfen

External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals

Open forum infectious diseases, 2019-04, Vol.6 (4), p.ofz110-ofz110

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 648

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(590)
Mit Volltextzugriff
(551)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(646)
Japanisch
(78)
Deutsch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(418)
Life Sciences & Biomedicine
(372)
Humans
(305)
Female
(138)
Male
(133)
Biological And Medical Sciences
(93)
Middle Aged
(85)
Adult
(79)
General & Internal Medicine
(76)
Infectious Diseases
(75)
Medical Sciences
(73)
Aged
(68)
Animals
(64)
Medicine, General & Internal
(63)
Immunology
(52)
Clinical Trials
(50)
Microbiology
(42)
Treatment Outcome
(41)
Surgery
(40)
Anti-Bacterial Agents - Therapeutic Use
(38)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Biomarkers and surrogate endpoints in clinical trials

Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022

Improving the Evidence for New Interventions in Infectious Diseases: Refocusing on Patients Instead of Pathogens and Direct Evidence for Added Patient Benefits

Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents

Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force

Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)

Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Effect of 7 vs 14 Days of Antibiotics Among Afebrile Men With Urinary Tract Infection

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine: A Critical Step for Developing Risk Management Strategies for the Use of Antimicrobials in Food Production Animals

Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation

Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross‐sectional study

Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective

Trends in Antimicrobial Drug Development: Implications for the Future

Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study

Factor Analysis in Distinguishing Coronavirus Disease 2019 From Other Influenza-like Illness Using a Validated Patient-Reported Outcome Instrument FLU-PRO Plus: A Prospective Real-world Cohort Study

Fluoroquinolone-Resistant Campylobacter Species and the Withdrawal of Fluoroquinolones from Use in Poultry: A Public Health Success Story

A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas

Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model

Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence

External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals

Suchergebnisse filtern